Immunoglobulin Levels Amongst Persons with and without Human Immunodeficiency Virus Type 1 Infection in Uganda and Norway

Scandinavian Journal of Immunology

Volumn 59, Issue 2, 2004, Pages 203-208

  Lugada, E S ^a,b   Mermin, J ^b   Asjo, B ^c   Kaharuza, F ^b   Downing, R ^b   Langeland, N ^c   Ormaasen, V ^d   Bruun, J ^d   Awor, A C ^b   Ulvestad, E ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; NORWAY; PRIORITY JOURNAL; T LYMPHOCYTE; UGANDA;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULINS; MALE; MIDDLE AGED; NORWAY; STATISTICS, NONPARAMETRIC; UGANDA;

EID: 10744225037     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01376.x     Document Type: Article

References (30)

1. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983;309:453-8.
2. + T helper cell depletion occurs. J Clin Invest 1988;82: 1908-14.
3. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992;89:561-6.
4. Mizuma H, Litwin S, Zolla-Pazner S. B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin Exp Immunol 1988;71:410-6.
5. Fenyo EM, Albert J, McKeating J. The role of the humoral immune response in HIV infection. Aids 1996;10 (Suppl. A):S97-106.
6. Subbramanian RA, Xu J, Toma E et al. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients. J Clin Microbiol 2002;40:2141-6.
7. Burrer R, Salmon-Ceron D, Richert S et al. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients. J Virol 2001;75:5421-4.
8. Moja P, Tranchat C, Tchou I et al. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients. J Infect Dis 2000;181:1607-13.
9. Ljunggren K, Broliden PA, Morfeldt-Manson L, Jondal M, Wahren B. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol 1988;73:343-7.
10. Lyamuya EF, Maselle SY, Matre R. Serum immunoglobulin profiles in asymptomatic HIV-1 seropositive adults and in patients with AIDS in Dar es Salaam, Tanzania. East Afr Med J 1994;71:24-8.
11. Peng XX, Wainberg MA, Tao Y, Brenner BG. Immunoglobulin and complement complexes in blood following infection with human immunodeficiency virus type 1. Clin Diagn Lab Immunol 1996;3: 128-31.
12. Grundbacher FJ. Heritability estimates and genetic and environmental correlations for the human immunoglobulins G, M, and A. Am J Hum Genet 1974;26:1-12.
13. Kovacsovics-Bankowski M, Carini C, Kashala O, Essex M. Isotypic distribution of HIV-1-specific antibodies in individuals from central Africa. Viral Immunol 1992;5:243-8.
14. Uko GP, Griffiths M, Dawkins RL et al. IgG2 associated hypergammaglobulinaemia in some Nigerians with HIV infection. Afr J Med Med Sci 1994;23:385-9.
15. Quinn TC, Piot P, McCormick JB et al. Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. JAMA 1987;257:2617-21.
16. Notermans DW, de Jong JJ, Goudsmit J et al. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses 2001;17:1003-8.
17. Morris L, Binley JM, Clas BA et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998;188:233-45.
18. Weidle PJ, Malamba S, Mwebaze R et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002;360:34-40.
19. Baumgarth N. A two-phase model of B-cell activation. Immunol Rev 2000;176:171-80.
20. Morell A, Skvaril F, Steinberg AG, Van Loghem E, Terry WD. Correlations between the concentrations of the four sub-classes of IgG and Gm Allotypes in normal human sera. J Immunol 1972;108:195-206.
21. Roitt IM, Brostoff J, Male DK. Immunology, 3rd edn. St. Louis, MO: Mosby, 1993.
22. Mazzoli S, Lopalco L, Salvi A et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999;180:871-5.
23. Broliden K, Hinkula J, Devito C et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001;79:29-36.
24. Kozlowski P, Buckheit RW, Jackson S. Neutralization of HIV infection by serum IgA antibodies. Adv Exp Med Biol 1995;371B: 1027-30.
25. Prince HE, Kleinman S, Czaplicki C, John J, Williams AE. Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J Acquir Immune Defic Syndr 1990;3:525-30.
26. Phillips AN, Sabin CA, Elford J, Bofill M, Lee CA, Janossy G. CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. Aids 1993;7:975-80.
27. Sabin CA, Devereux H, Phillips AN, Janossy G, Loveday C, Lee CA. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. Aids 1998;12:1347-52.
28. Ullum H, Lepri AC, Katzenstein TL et al. Prognostic value of single measurements of beta-2-microglobulin, immunoglobulin A in HIV disease after controlling for CD4 lymphocyte counts and plasma HIV RNA levels. Scand J Infect Dis 2000;32:371-6.
29. Boyd JE, James K. B cell responses to HIV and the development of human monoclonal antibodies. Clin Exp Immunol 1992;88:189-202.
30. Voltersvik P, Albrektsen G, Ulvestad E, Dyrhol-Riise AM, Sørensen B, Åsjö B. Changes in immunoglobulin isotypes and IgG subclasses during HAART: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J Acquir Immune Defic Syndr 2003;34:358-67.